General hospitals can now prescribe ‘Onureg,’ an oral acute myeloid leukemia drug.

According to industry sources, BMS Pharmaceutical Korea’s Onureg (azacitidine), a new drug for treating acute myeloid leukemia (AML), has recently passed the Drug Committee (DC) of Big 5 tertiary general hospitals, including Samsung Seoul Hospital, Seoul National University Hospital, Seoul St. Mary's Hospital, Seoul Asan Hospital, and Sinchon Severance Hospital, as well as 40 hospitals across the country.

Onureg received approval in Korea in March 2022 and passed the Health Insurance Review and Assessment Service's (HIRA) Cancer Drug Review Committee in December of the same year. Subsequently, O